Propoxycaine

Summary

Propoxycaine (CHEMBL1195) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 294.39 Da · C16H26N2O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1195
Name	Propoxycaine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	6843
Molecular formula	C16H26N2O3
Molecular weight	294.39
InChIKey	CAJIGINSTLKQMM-UHFFFAOYSA-N

SMILES: CCCOC1=C(C=CC(=C1)N)C(=O)OCCN(CC)CC

IUPAC name: 2-(diethylamino)ethyl 4-amino-2-propoxybenzoate

Also known as: Propoxicaina, Propoxycaine, SID11112410, propoxycaine, PROPOXYCAINE

Parent form; salt/anhydrous children: CHEMBL1769

Patent coverage: 1,677 distinct patent families (5,653 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 5,144 (91%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Sodium channel alpha subunits; brain (Types I, II, III), Cytochrome P450 2D6, Cytochrome P450 1A2.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 4 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CYP2D6	5.7	Potency	1995	nM	CHEMBL_ACT_5006506
CYP2D6	5.7	AC50	1995	nM	CHEMBL_ACT_5987301

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).